Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03821857 · ClinicalTrials.gov registry record · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
A Phase 4 study of Alzheimer Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 614
- Enrollment target
- 2
- Study locations
NCT03821857: Recruiting Phase 4 study of Alzheimer Disease, sponsored by Mayo Clinic.
NCT03821857 is a Phase 4 study of Alzheimer Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 614 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03821857, a Phase 4 study of Alzheimer Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 614 participants
- Enrollment target
- 2
- Study locations
Study Summary
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Primary Outcome
Cortical 18F-Flortaucipir PET imaging measured once in each participant
Conditions Studied
Interventions
- DRUG 18-F-Flortaucipir
Study Locations (2)
Florida
- Mayo Clinic - Jacksonville
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2030-05 |
| Phase | Phase 4 |
What NCT03821857 shows while recruiting
NCT03821857 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which 18-F-Flortaucipir is the first listed.
NCT03821857 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03821857 about?
NCT03821857 is a clinical study titled "Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease". The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
What is the current status of trial NCT03821857?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 614 participants. The study started on 2019-06-27. Estimated completion is 2030-05.
What conditions does trial NCT03821857 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03821857?
The interventions under investigation include: 18-F-Flortaucipir (DRUG).
Who is sponsoring clinical trial NCT03821857?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03821857 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03821857's enrollment target sits among peer trials
614 44th of 306 higher than 263 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
ACTIVE NOT RECRUITING · Phase 4
-
The Depression in Alzheimer's Disease Study (DIADS)
COMPLETED · Phase 4
-
Antipsychotic Discontinuation in Alzheimer's Disease
COMPLETED · Phase 4
-
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- NCT07409272 · 614 participants · Phase 3
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- NCT06593652 · 615 participants · NA
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI